84 WangD
Wegovy's list price is approximately $1,350 per month for the 2.4 mg maintenance dose
When you're ready to ensure your research is built on a foundation of quality, we're here to help you Get Started Today
That progression is typical
It's an investigational drug currently in Phase 3 clinical trials Eli Lilly's TRIUMPH Phase 3 program includes multiple trials for obesity, type 2 diabetes, NASH, and cardiovascular outcomes Expected timeline: FDA submission in 2026, potential approval in 20272028 Phase 2 results showed 24.2% weight loss at 48 weeks, the highest ever recorded for a GLP-1 class medication How to access now: Clinical trial enrollment (free), compounding pharmacies (with important legal caveats), or research peptides (grey market) When approved, retatrutide will be the first triple-agonist obesity medication (GLP-1 + GIP + glucagon) Is Retatrutide FDA Approved
Future studies can consider more flexible methods to handle possible non-linear relationships to improve understanding and accuracy